Managing Patients with Neurogenic Detrusor Overactivity A Global Approach
|
|
- Shon Murphy
- 5 years ago
- Views:
Transcription
1 european urology supplements 5 (2006) available at journal homepage: Managing Patients with Neurogenic Detrusor Overactivity A Global Approach Pierre Denys *, Alexis Schnitzler, Nicholas Roche Department of Physical Medicine and Rehabilitation, Neuro-Urology Unit, Hôpital Raymond Poincaré, Garches, France Article info Keywords: Global patient management Multidisciplinary Neurogenic overactive bladder Urinary incontinence Abstract Patients with neurogenic detrusor overactivity (NDO) usually have other disorders or disabilities, in addition to bladder dysfunction, that require treatment. A number of different medical specialists are, therefore, involved in the management of an individual patient and may well be working towards different treatment goals. This, together with the possible impact on NDO of treatments for other disabilities and vice versa, means that a global approach to management of a given patient is needed to ensure that patients receive the best possible treatment for all their conditions. This is particularly true for treatments that are used for multiple indications in the same patient, such as botulinum toxin, which has been used for many years as an effective treatment for dystonia and spasticity, and has more recently shown promise in the treatment of NDO and idiopathic detrusor overactivity. The appropriate choice of total dose and staging of dosing is required to maximise safety and efficacy in both indications. Development of multidisciplinary treatment algorithms for the various types of NDO patients could help to promote a global approach to the management of these individuals and to optimise their care. # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Hôpital Raymond Poincaré, Netter Building, 104 Boulevard Raymond Poincaré, F Garches, France. Tel ; Fax: address: pierre.denys@rpc.ap-hop-paris.fr (P. Denys). 1. Introduction Individuals with neurogenic detrusor overactivity (NDO) are some of the most challenging patients to manage [1]. Not only does their bladder dysfunction arise in conjunction with a range of underlying conditions (e.g., spinal cord injury [SCI], multiple sclerosis [MS], diabetes, stroke, and Parkinson disease), but within each condition the severity of NDO can vary widely. This means that the clinical characteristics of patients with NDO vary greatly. Thus, management largely needs to be considered on an individual basis. The situation is further complicated by the fact that there is little correlation between the signs and severity of symptoms of urinary incontinence (UI), so that both need to be considered to gain a clear picture of bladder dysfunction and its impact on the patient [2]. The frequency of other secondary conditions or disorders, such as cognitive impairment, upper limb dysfunction, sexual dysfunction, bowel dysfunction, and neurogenic pain, adds a further level of complexity to the management of many patients. These are in addition to the normal range of /$ see front matter # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eursup
2 692 european urology supplements 5 (2006) diseases, such as hypertension, infections, and allergy, that are experienced by the nonneurogenic bladder population; these diseases need to be considered when managing these patients. The situation is made even more challenging by the involvement of many different medical specialties in the management of such patients; for example, neurology, physical medicine and rehabilitation, pain management, urology, and gynaecology, each of which has its own specific primary goal of treatment. The choice of specialist to whom patients are initially referred depends on their primary disorder. The primary specialist may then refer patients to other specialists for the management of specific secondary disorders, such as UI, or may initiate treatment themselves and only refer patients in cases of treatment failure or when more specialised treatment is required. This has important implications for the management of UI in neurogenic patients. First, various different specialists are involved in the management of UI. For example, patients with SCI are generally referred to rehabilitation specialists who often initiate treatments for UI, whereas patients with MS are referred to neurologists who then refer their patients to a urologist when they deem treatment for UI to be appropriate. Whereas a urologist will clearly be aware of the most appropriate and effective treatments for UI, other specialists may be less aware of the available options as their focus is on other aspects of the patient s condition. The aim of treatment, as well as the specific therapy chosen, is likely to reflect who treats the patient, as well as the clinical characteristics of their UI. For example, the initial goal of the neurologist in the management of an MS patient who has recently received steroids for an acute exacerbation of the primary disease is to control urinary tract infection. This is as a result of the risk of severe infection associated with this therapy. Second, patients may well be receiving treatments from a number of different specialists and the different treatments may have an impact on other disorders [3 8]. Third, with the involvement of multiple specialists, responsibility for patient follow-up can become unclear and may lead to suboptimal treatment in the long term. Despite these multiple challenges, achieving the optimal management of UI symptoms is clearly very important for neurogenic patients. For patients with SCI or spina bifida, management of NDO is important for the minimisation of risk of damage to the upper urinary tract and renal failure. However, for all neurogenic patients, control of UI symptoms is essential to minimise the impact of UI on their quality of life (QOL) and general well-being [9 11]. Symptoms of UI can profoundly affect self-confidence and self-esteem, as well as limit willingness or ability to lead a normal life. Indeed, for some patients, symptoms of UI may be more distressing and inconvenient than those of the primary condition. For patients with a degree of disability, inadequately managed symptoms can also increase dependence on caregivers, which can have a further negative impact on self-esteem and QOL. Therefore, management of UI is an important part of the care of all neurogenic patients with bladder dysfunction. 2. Treatment considerations There are a number of options for the management of NDO. Pharmacotherapy with anticholinergic therapies, together with intermittent self-catheterisation, is the first-line treatment of choice for most patients. However, responses to anticholinergic therapies are variable and many patients discontinue therapy due to unacceptable side-effects, a particular problem at the higher doses that are required by many neurogenic patients or the inconvenience of daily therapy. Transdermal patches have been developed as an alternative delivery format and have been better tolerated than oral administration [12], whereas intravesical administration of anticholinergics has been used, particularly in children and adolescents, but is yet to be approved [13,14]. However, both alternatives require frequent dosing and intravesical formulations cannot easily be self-administered, increasing the complexity and cost of treatment. Other options include a-blockers, neuromodulation, and surgery (bladder augmentation), as well as treatments that are currently not approved for use in the bladder, such as botulinum toxin. Although data from clinical trials give an indication of the efficacy and safety profile for the available options, the choice of the most appropriate therapy for the individual patient is more complex and should consider various patient-specific factors. For example, whether there are likely to be interactions between the proposed NDO treatment and any other treatments that the patient is receiving must be considered. This is of particular importance when considering the use of botulinum toxin type A (BoNTA). BoNTA has been used in the treatment of dystonia and spasticity for many years and is highly effective for reducing the disabilities that are associated with
3 european urology supplements 5 (2006) Table 1 Treatments commonly used in neurologic patients that could affect bladder function Treatment Indication Consequence/consideration Treatment having a positive effect on bladder function/symptoms Anticholinergics Parkinson disease Constipating side-effects should be Depression (tricyclic antidepressants) Allergy (antihistamines) considered in patients with bowel dysfunction Baclofen Spasticity Modulates detrusor contraction strength MS and micturition characteristics Apomorphine/L-dopa Parkinson disease May alleviate voiding difficulty but has been shown to aggravate urgency and urge incontinence Treatment having a potentially negative effect Corticosteroids Acute MS relapse Increased susceptibility to infection (especially UTI) Deep brain stimulation Parkinson disease Change bladder storage characteristics Antibiotics (aminoglycosides) UTIs Potential nephrotoxicity Acetylcholinesterase inhibitors Alzheimer disease Prolong effects of acetylcholine (counteracts effects of anticholinergics) MS = multiple sclerosis; UTI = urinary tract infection. these conditions. More recently, BoNTA has been showntobeeffectiveinreducingthesymptomsof UI that are associated with NDO [15 18]. Therefore, to ensure that the patient gains maximum benefit from BoNTA in the treatment of both conditions, appropriate choice of the total dose and staging of dosing is required. Possible interactions between treatments for bladder dysfunction and the primary disorder also need to be considered when different therapies are proposed for the management of the different disorders (Table 1). Some treatments for NDO can help decrease spasticity and permit sexual function, thus making them particularly appropriate for patients with these conditions. Similarly, baclofen, which is used to relieve spasticity and apomorphine, or L-dopa, which is used in the treatment of Parkinson disease, can both improve bladder function [3 5]. However, some treatments for primary conditions can adversely affect bladder function, for example, deep brain stimulation treatment for Parkinson disease [7,8]. The overall medication and side-effect burden that patients may experience as a result of all the treatments they are receiving also needs to be considered, especially because this is likely to affect patient satisfaction and long-term compliance with treatment. In this respect, one-off procedures such as surgery offer some benefits because compliance is not an issue. However, many patients may be unwilling to undergo an irreversible treatment, particularly if it is likely to limit their treatment options in the future. In addition, the risk of complications and patient fitness to undergo surgical procedures need to be considered. 3. A global approach to management The current International Continence Society Guidelines [19,20] contain a comprehensive section on the evaluation and management of neurologic UI as well as a review of the data generated to date with pharmacologic therapies thought to be of value in managing UI, regardless of its cause. The specificity of the recommendations for each subpopulation of neurogenic bladder is enhanced by the splitting of patients and stages of therapy by site of lesion and certain patient specifics, such as cooperative or uncooperative and with or without detrusor sphincter dyssynergia. Although undoubtedly a valuable reference source, the documents are largeandcanbeexpensivetoobtain,whichmay limit their use [21]. Furthermore, nonurologic specialists may be unaware of such guidelines or not have the time to keep abreast of latest developments in the diversity of other associated conditions in addition to those focussing on their own speciality. This clearly has implications in terms of adherence to best practice guidelines and awareness of alternative approaches to UI management. To take into account the possible interactions between the different treatments patients with NDO are likely to require and their overall impact on the patient, a multidisciplinary approach is clearly required. This would allow the total treatment needs for the individual patient to be considered so that maximum improvement is gained across the range of symptoms and disabilities, with minimal tolerability or compliance issues.
4 694 european urology supplements 5 (2006) Such an approach necessitates interactions among all the specialties that are involved in the management of these patients. Whereas the value of such an approach can be readily accepted, achieving this in practice is much more difficult. Ideally, this would be achieved by face-to-face discussions among the specialists who are involved in the management of a given patient, but this is clearly impractical as well as time-consuming. An alternative approach would be to involve such specialists in the development of treatment algorithms for the main types of patient. The algorithms would include details of the possible approaches for different types of patient, appropriate points for referral, and recommendations for who should follow up the patient and in what time frame. Ideally, such algorithms would be produced on a local basis to ensure their applicability to each centre. In addition, local involvement should help encourage widespread awareness of the availability of guidelines and adherence to the recommendations, potentially overcoming some of the barriers to uptake seen with the internationally produced guidelines, highlighted above. Production of such algorithms should not only help patients to receive the treatment they deserve, but would also help promote a greater understanding of UI and its effect on QOL and daily functioning among all specialists who are involved in managing neurogenic patients. In addition, sharing of expertise across disciplines should help to ensure that all specialties are aware of current developments in the management of UI so that patients can have access to the most effective treatments that are currently available. 4. Conclusions Managing the symptoms of UI is an important part of the treatment of neurogenic patients, given the impact of symptoms on the patient s well-being and the risk of further damage for some patients if NDO is not treated appropriately. However, most patients with NDO have other disorders and disabilities that require medical treatment and often take priority over the management of NDO. Treatment of NDO therefore needs to be considered within the context of the patient s other medical conditions. This is particularly important given that treatments for the other medical conditions may have an impact on NDO and vice versa. A global approach to the management of patients with NDO should allow treatments for the different disorders to be coordinated. Ideally, this would be achieved by discussions among the specialists who are involved in the management of a given patient. However, given the impracticality of such an approach, the local, multidisciplinary development of treatment guidelines could be used to promote a global approach to the management of individual patients. This would allow patients to gain the maximum benefit from therapy and improvement in their QOL. Conflict of interest Professor Denys has been an investigator and consultant for Allergan, and an investigator for Medtronic. Acknowledgements This article forms part of a supplement based on an International Continence Society workshop Botulinum Toxin in the Overactive Bladder held in Montreal, August 2005, and supported by an unrestricted educational grant from Allergan. References [1] Denys P, Corcos J, Everaert K, et al. Improving the global management of the neurogenic bladder patient: part I. The complexity of patients. Curr Med Res Opin 2006; 22: [2] Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol 1999;161: [3] Andersson KE, Pehrson R. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 2003;63: [4] Watanabe T, Perkash I, Constantinou CE. Modulation of detrusor contraction strength and micturition characteristics by intrathecal baclofen in anesthetized rats. J Urol 1997;157: [5] Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 1993; 12: [6] Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Shortterm effect of a single levodopa dose on micturition disturbance in Parkinson s disease patients with the wearing-off phenomenon. Mov Disord 2003;18: [7] Seif C, Herzog J, van der Horst C, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 2004;55: [8] Dalmose AL, Bjarkam CR, Sorensen JC, Djurhuus JC, Jorgensen TM. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourol Urodyn 2004;23: [9] Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 2000;13: [10] Westgren N, Levi R. Quality of life and traumatic spinal cord injury. Arch Phys Med Rehabil 1998;79:
5 european urology supplements 5 (2006) [11] Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil 2001;80: [12] Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166: [13] Buyse G, Verpoorten C, Vereecken R, Casaer P. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. J Urol 1998;160: [14] Saito M, Watanabe T, Tabuchi F, et al. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol 2004;11: [15] Stohrer M, Schurch B, Kramer G, et al. Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 1999;18: [16] Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-a toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45: [17] Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patient with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47: [18] Schurch B, de Seze M, Denys P, et al. Botulinum toxin is a safe and effective treatment for neurogenic urinary incontinence: results from a single-treatment, randomized, placebo-controlled 6-month study. J Urol 2005; 174: [19] Wyndaele JJ, Castro D, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khuory S, Wein A, editors. Incontinence, vol 2. Management. Plymouth, United Kingdom: Health Publication; p [20] Anderson KE, Appell R, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khuory S, Wein A, editors. Incontinence, vol 2. Management. Plymouth, United Kingdom: Health Publication; p [21] Zielstorff RD. Online practice guidelines: issues, obstacles, and future prospects. J Am Med Inform Assoc 1998;5:
2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationOnabotulinumtoxin - A Injections for the Treatment of Neurogenic Detrusor Overactivity
Onabotulinumtoxin - A Injections for the Treatment of Neurogenic Detrusor Overactivity Raluca Borcăiaș 1, S. Rașcu 1,2, V. Jinga 1,2, D. Mischianu 1,3, A. Manu-Marin 4 1 Carol Davila University of Medicine
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1729 1735 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Do Repeat Intradetrusor Botulinum Toxin Type A Injections Yield Valuable
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationPelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS
Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS OhioHealth, Columbus Ohio Disclosures I have nothing to disclose Objectives Describe the role of a pelvic floor therapist in
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Limited text update March 2015) B. Blok (Co-chair), J. Pannek (Co-chair), D. Castro Diaz, G. del Popolo, J. Groen, T. Gross (Guidelines ssociate), R. Hamid, G. Karsenty, T.M.
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationHow to manage a patient with bladder dysfunction
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 13 How to manage a patient with autonomic dysfunction - Level 2 How to manage a patient with
More informationGUIDELINES ON NEURO-UROLOGY
GUIDELINES ON NEURO-UROLOGY (Text update pril 2014) J. Pannek (co-chair), B. Blok (co-chair), D. Castro-Diaz, G. del Popolo, J. Groen, G. Karsenty, T.M. Kessler, G. Kramer, M. Stöhrer Eur Urol 2009 Jul;56(1):81-8
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationNeuropathic Bladder. Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014
Neuropathic Bladder Magda Kujawa Consultant Urologist Stockport NHS Foundation Trust 12/03/2014 Plan Physiology- bladder and sphincter behaviour in neurological disease Clinical consequences of Symptoms
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationNEUROMODULATION FOR UROGYNAECOLOGISTS
NEUROMODULATION FOR UROGYNAECOLOGISTS Introduction The pelvic floor is highly complex structure made up of skeletal and striated muscle, support and suspensory ligaments, fascial coverings and an intricate
More informationMultiple Sclerosis. Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
Queen Square Uro-neurology course, London, UK 20 th -21 st October 2016 Multiple Sclerosis Véronique Phé, MD, PhD Pitié-Salpêtrière Academic Hospital Department of Urology Paris 6 University Paris, FRANCE
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationIncontinence in neurological disease
nice bulletin Incontinence in neurological disease NICE provided the content for this booklet which is independent of any company or product advertised NICE Bulletin - Incontinence in neurological disease.indd
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationGOVINDARAJ N. RAJKUMAR, DOUGLAS R. SMALL, ABDUL W. MUSTAFA and GRAEME CONN Department of Urology, Southern General Hospital, Glasgow, UK
Original Article BTXA IN DETRUSOR FOR REFRACTORY IDIOPATHIC DOA RAJKUMAR et al. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of
More informationUse of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity
Use of the Botulinum Toxin A in the Treatment of the Neurogenic Detrusor Overactivity Editorial Raluca Borcăiaș 1,2, A. Manu-Marin 3, S. Nedelea 1,2, S. Rascu 1,2, V. Jinga 1,2 1 Prof. Dr. Th. Burghele
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationThis Special Report supplement
...INTRODUCTION... Overactive Bladder: Defining the Disease Alan J. Wein, MD This Special Report supplement to The American Journal of Managed Care features proceedings from the workshop, Overactive Bladder:
More informationContinence. Who cares and does it matter? Dr Carl Hanger Geriatrician, CDHB SI Alliance Stroke Education Day 2/11/17
Continence. Who cares and does it matter? Dr Carl Hanger Geriatrician, CDHB SI Alliance Stroke Education Day 2/11/17 1500 pages, leading stroke experts Does it Matter? Definitely! Patient Dignity / QOL
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationClinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg148
Urinary incontinence in neurological disease: assessment and management Clinical guideline Published: 8 August 2012 nice.org.uk/guidance/cg148 NICE 2018. All rights reserved. Subject to Notice of rights
More informationIT IS WELL RECOGNIZED that urinary incontinence can
646 ORIGINAL ARTICLE Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence Brigitte Schurch, MD, Pierre Denys, MD, Chris M. Kozma,
More informationBladder Dysfunction in Multiple Sclerosis. by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN
Clinical Bulletin Information for Health Professionals Bladder Dysfunction in Multiple Sclerosis by Nancy J. Holland, EdD, RN and Nancy C. Reitman, MA, RN Effective bladder management strategies make it
More informationINVESTIGATION AND MANAGEMENT OF NEUROGENIC BLADDER DYSFUNCTION
INVESTIGATION AND MANAGEMENT OF NEUROGENIC BLADDER DYSFUNCTION See end of article for authors affiliations Correspondence to: Professor Clare Fowler, Department of Uro- Neurology, National Hospital for
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationUrodynamics in Neurological Lower Urinary Tract Dysfunction. Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne
Urodynamics in Neurological Lower Urinary Tract Dysfunction Mr Chris Harding Consultant Urologist Freeman Hospital Newcastle-upon-Tyne Learning Objectives Review functional neurology relevant to lower
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationThe Epidemiology and Pathophysiology of Neurogenic Bladder
n reports n The Epidemiology and Pathophysiology of Neurogenic Bladder David Ginsberg, MD Neurogenic Bladder: An Introduction Normal micturition (urination) requires proper function of both the bladder
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2016) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler. Guidelines Associates:
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationStimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury. Original Policy Date
MP 7.01.58 Stimulation of the Sacral Anterior Root Combined with Posterior Sacral Rhizotomy in Patients with Spinal Cord Injury Medical Policy Section Issue 12:2013 Original Policy Date 12:2013 Last Review
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2013) 30:819 833 DOI 10.1007/s25-013-0054-z ORIGINAL RESEARCH OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationDRUG FORECAST. Select Conditions of the Lower Urinary Tract
Transdermal Oxybutynin: Novel Drug Delivery for Overactive Bladder Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD INTRODUCTION
More informationOriginal Article. Annals of Rehabilitation Medicine INTRODUCTION
Original Article Ann Rehabil Med 2014;38(3):342-346 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2014.38.3.342 Annals of Rehabilitation Medicine Phasic Changes in Bladder Compliance
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationeuropean urology 50 (2006)
european urology 50 (2006) 806 810 available at www.sciencedirect.com journal homepage: www.europeanurology.com Neuro-urology Successful Treatment with Intradetrusor Botulinum-A Toxin for Urethral Urinary
More informationUrinary Incontinence. Lora Keeling and Byron Neale
Urinary Incontinence Lora Keeling and Byron Neale Not life threatening. Introduction But can have a huge impact on quality of life. Two main types of urinary incontinence (UI). Stress UI leakage on effort,
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationEAU GUIDELINES ON NEURO-UROLOGY
EAU GUIDELINES ON NEURO-UROLOGY (Limited text update March 2017) B. Blok (Co-chair), J. Pannek (Co-chair) D. Castro-Diaz, G. del Popolo, J. Groen, R. Hamid, G. Karsenty, T.M. Kessler Guidelines Associates:
More informationThe Effect ofverapamil on the Treatment of Detrusor Hyperreflexia in the Spinal Cord Injured Population
Paraplegia 27 (1989) 364-369 0031-1758/89/0027-0364$10.00 ([j 1989 International Medical Society of Paraplegia The Effect ofverapamil on the Treatment of Detrusor Hyperreflexia in the Spinal Cord Injured
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationBotulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction
European Urology European Urology 48 (2005) 984 990 Botulinum-AToxin Detrusor and Sphincter Injection in Treatment of Overactive Bladder Syndrome: Objective Outcome and Patient Satisfaction Heinrich Schulte-Baukloh
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationSELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More informationBOTULINUM TOXIN POLICY TO INCLUDE:
BOTULINUM TOXIN POLICY TO INCLUDE: Blepharospasm in adults, Hemi facial spasm in adults, spasmodic torticollis (cervical dystonia), focal spasticity treatment of dynamic equinus foot deformity, focal spasticity
More informationSpinal Cord Injury. R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH
Spinal Cord Injury R Hamid Consultant Neuro-Urologist London Spinal Injuries Unit, Stanmore & National Hospital for Neurology & Neurosurgery, UCLH SCI 800 1000 new cases per year in UK Car accidents 35%
More informationIntroduction. Spinal Cord Injury (SCI) Is it necessary to perform surveillance investigations for long term follow up of spinal cord injury patients?
Is it necessary to perform surveillance investigations for long term follow up of spinal cord injury patients? Rizwan Hamid MBBS, FRCSEd, FRCS(Urol), MD(Res) Honorary Senior Lecturer & Consultant Urologist
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationGUIDELINES ON URINARY INCONTINENCE
12 GUIDELINES ON URINARY INCONTINENCE (Text updated March 2005) J. Thüroff, (chairman), P. Abrams, K.E. Andersson, W. Artibani, E. Chartier-Kastler, C. Hampel, Ph. van Kerrebroeck Introduction The condition
More informationINTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE
PEDIATRIC UROLOGY INTRAVESICAL INJECTION OF BOTULINUM TOXIN TYPE A: MANAGEMENT OF NEUROPATHIC BLADDER AND BOWEL DYSFUNCTION IN CHILDREN WITH MYELOMENINGOCELE ABDOL-MOHAMMAD KAJBAFZADEH, SHAHRAM MOOSAVI,
More informationNeuro-urology for the Urogynaecologist and urologist W20, 15 October :00-18:00
Neuro-urology for the Urogynaecologist and urologist W20, 15 October 2012 14:00-18:00 Start End Topic Speakers 14:00 14:05 Introduction to the Workshop Sohier Elneil 14:05 14:25 Neurology of the Bladder
More informationNeurogenic Bladder. Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, Eric Levey, M.D.
Neurogenic Bladder Spina Bifida Education Day Conference SBA of Northeastern New York Albany, New York April 14, 2018 Eric Levey, M.D. Pediatrics & Neurodevelopmental Disabilities Chief Medical Officer,
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH MICHIGA Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More information/05/ /0 Vol. 174, , July 2005 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/05/1741-0196/0 Vol. 174, 196 200, July 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000162035.73977.1c BOTULINUM TOXIN TYPE
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationA review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals
264 Central European Journal of Urology REVIEW PAPER FUNCTIONAL UROLOGY A review of prospective Clinical Trials for neurogenic bladder: Pharmaceuticals Cristian Persu 1, Emmanuel Braschi 2, John Lavelle
More information3/20/10. Prevalence of OAB Men: 16.0% Women: 16.9% Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Dry. Population (millions) Wet
1 Prevalence of OAB Men: 16.0% Women: 16.9% Stewart WF, et al. World J Urol. 2003;20:327-336. Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Stewart WF, et al. World J Urol. 2003;20:327-336.
More informationExperience with Different Botulinum Toxins for the Treatment of Refractory Neurogenic Detrusor Overactivity
Neurourology Botulinum Toxins for Refractory Detrusor Overactivity International Braz J Urol Vol. 36 (1): 66-74, January - February, 2010 doi: 10.1590/S1677-55382010000100011 Experience with Different
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationAdverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome
EUROPEAN UROLOGY 58 (2010) 919 926 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 BOTOX 50 ALLERGAN UNITS, powder for solution for injection Powder in vial (type I glass) supplied with
More informationAalborg Universitet. Published in: Journal of Urology. DOI (link to publication from Publisher): /01.ju b
Aalborg Universitet Treatment of neurogenic detrusor overactivity in spinal cord injured patients by conditional electrical stimulation Hansen, John; Media, S.; Nøhr, M.; Biering-Sørensen, F.; Sinkjær,
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationEfficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study
American Journal of Obstetrics and Gynecology (2005) 192, 1735 40 www.ajog.org Efficacy of botulinum-a toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study Matthias
More informationPosterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial
ORIGINAL ARTICLE Posterior Tibial Nerve Stimulation for Treating Neurologic Bladder in Women: a Randomized Clinical Trial Tahereh Eftekhar 1, Nastaran Teimoory 1, Elahe Miri 1, Abolghasem Nikfallah 2,
More informationVarious Types. Ralph Boling, DO, FACOG
Various Types Ralph Boling, DO, FACOG The goal of this lecture is to increase assessment and treatment abilities for physicians managing urinary incontinence (UI) patients. 1. Effectively communicate with
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationParkinson s Disease and Multiple System Atrophy
Parkinson s Disease and Multiple System Atrophy Jalesh N. Panicker MD, FRCP Department of Uro-Neurology National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen Square, London
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationeuropean urology 53 (2008)
european urology 53 (2008) 275 287 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology Botulinum Toxin A (Botox W ) Intradetrusor Injections in Adults with
More informationGUIDELINES ON URINARY INCONTINENCE
GUIDELINES ON URINARY INCONTINENCE 9 J. Thüroff, (chairman), P. Abrams, J-T. Andersen, W. Artibani, E. Chartier-Kastler, C. Hampel, M. Hohenfellner, T. Tammela, Ph. van Kerrebroeck Introduction The condition
More informationPhysiology & Neurophysiology of lower U.T.
Physiology & Neurophysiology of lower U.T. Classification of voiding dysfunction Evaluation of a child with voiding dysfunction Management Storage Ø Adequate volume of urine Ø At LOW pressure Ø With NO
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationUniversity of Alberta Reconstructive Urology Fellowship
FACULTY OF MEDICINE AND DENTISTRY DEPARTMENT OF SURGERY DIVISION OF UROLOGY Keith Rourke, MD, FRCSC Reconstructive Urology Professor Chair of Academic Urology Reconstructive Urology Fellowship Director
More informationMechanisms of Disease: central nervous system involvement in overactive bladder syndrome
Mechanisms of Disease: central nervous system involvement in overactive bladder syndrome Karl-Erik Andersson SUMMARY The pathophysiology of overactive bladder syndrome (OABS) and detrusor overactivity
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 891 896 available at www.sciencedirect.com journal homepage: www.europeanurology.com Incontinence Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory
More informationGeneral introduction
General introduction http://hdl.handle.net/1765/103217 General introduction General introduction 1 2 Erasmus Medical Center Rotterdam General introduction 3 Functional pelvic floor disorders Symptoms related
More informationUrodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in children
ORIGINAL ARTICLE Vol. 41 (4): 739-743, July - August, 2015 doi: 10.1590/S1677-5538.IBJU.2014.0303 Urodynamic outcome of parasacral transcutaneous electrical neural stimulation for overactive bladder in
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationINTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET (version 2.0)
1 INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET (version 2.0) The first version of the International Spinal Cord Injury Lower Urinary Tract Function Basic Data Set (Biering-Sørensen
More informationSubjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented Goals the Search for Value
european urology supplements 6 (2007) 438 443 available at www.sciencedirect.com journal homepage: www.europeanurology.com Subjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented
More information